CEPBAEuropean Center for Parallelism of Barcelona (Technical University of Catalonia; Spain)
References in periodicals archive ?
Further risk stratification among the intermediate-risk group of patients with normal cytogenetics is possible with molecular analysis for mutations of the FLT-3, NPM1, CEPBA, RUNX1, MLL, and EVI1 genes.
1;q22) t(15;17)(q22; q21) Normal karyotype with mutated CEPBA, or mutated NPM1 without FLT-3 Intermediate: 41% Normal +8 +21 +22 del(7q) del(9q) Abnormal (11q23) Adverse: 14% Complex cytogenetics -5 del(5q) -7 Abnormal 3q